Durvalumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Durvalumab: From PD-L1 Blockade Therapy to Prostatic Urethra Urothelial Carcinoma
One-Sentence Summary
Durvalumab (brand name IMFINZI) is a PD-L1 blocking antibody marketed in the US as an injectable cancer immunotherapy. The TxGNN model predicts it may be effective for prostatic urethra urothelial carcinoma (score 99.98%). However, no clinical trials and no publications are currently linked to this specific site, so the prediction rests on model output and class-level reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Prostatic urethra urothelial carcinoma |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 listings (both under BLA761069) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Durvalumab is a monoclonal antibody that blocks PD-L1. This releases the brake that tumour cells place on T cells. Detailed mechanism data from DrugBank is not currently available, so this description relies on the drug’s known class behaviour.
Urothelial carcinoma is a tumour type in which PD-1/PD-L1 blockade is known to be active as a class. The prostatic urethra is a urothelium-lined site, so extending the same logic to it is biologically plausible. The high score probably reflects the graph proximity of this disease to other urothelial cancers.
This reasoning is indirect. No trial or publication is specific to the prostatic urethra, so the prediction is a hypothesis, not a finding.
Clinical Trial Evidence
Currently no related clinical trials registered for this indication.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA761069 | IMFINZI | Injection, solution | AstraZeneca Pharmaceuticals LP |
The data lists this authorization twice with identical details, so it is shown once here. Approved indication text was not provided.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (immune checkpoint inhibitor); not a conventional cytotoxic agent |
| Myelosuppression Risk | Low, based on general class knowledge; not confirmed from the package insert |
| Emetogenicity Classification | Low, based on general class knowledge |
| Monitoring Items | Immune-related adverse events: liver function, thyroid function, renal function, blood glucose, and pulmonary and gastrointestinal symptoms |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there is no trial or literature evidence for prostatic urethra urothelial carcinoma. The evidence level is L5, and the rationale is class-level only.
Two other TxGNN predictions for this drug have more supporting evidence and may be better starting points:
- Infiltrating bladder urothelial carcinoma, sarcomatoid variant (rank 3): a Phase 2 trial of durvalumab with neoadjuvant chemotherapy (NCT03912818) is directly relevant, but it was terminated after only 7 patients.
- Endocervical carcinoma (rank 6): a completed Phase 1 trial (NCT03452332) and an ongoing Phase 2 trial (NCT04065269) exist, but both involve combination regimens.
To proceed, the following is needed:
- A search for trials or case series in urothelial carcinoma involving the prostatic urethra, or in upper-tract or non-bladder urothelial cancers that could include this site
- Package insert warnings and contraindications (a blocking data gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for BLA761069, to confirm the original indication and its relationship to the predicted one
- Route compatibility assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.